Pipeline

Our current pipeline reflects our focus on fighting the opioid crisis in the U.S.

BRIXADI™️ [CAM2038 (buprenorphine) extended-release] weekly and monthly injection for OUD has registered for an NDA.

Learn more about the results of BRIXADI’s clinical trials:

FLUIDCRYSTAL®* INJECTION DEPOT TECHNOLOGY

Watch the video above for a description of FluidCrystal® Injection Depot Technology.

*FluidCrystal® trademark is owned by Camurus and used by Braeburn under license.

Define the future at Braeburn...together.